This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
by Zacks Equity Research
Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.
MRKPositive Net Change MRNAPositive Net Change HALOPositive Net Change TGTXPositive Net Change
biotechs
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
by Ekta Bagri
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
BMYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
by Sundeep Ganoria
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
NVONegative Net Change VKTXPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
by Zacks Equity Research
AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.
AZNNegative Net Change NVSPositive Net Change TVTXPositive Net Change
biotechs
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
by Kanishka Das
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
AXSMNegative Net Change JAZZPositive Net Change ACADPositive Net Change
biotechs
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
by Ahan Chakraborty
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
by Ekta Bagri
Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
by Sundeep Ganoria
MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.
MRNAPositive Net Change GSKNegative Net Change PFEPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals vaccines
Biotech ETF (BBH) Hits New 52-Week High
by Sanghamitra Saha
BBH hits a 52-week high as positive Amgen news and strong momentum fuel gains. Can the biotech ETF rally further?
BBHPositive Net Change
biotechs etfs
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
by Ahan Chakraborty
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
BIIBPositive Net Change VKTXPositive Net Change NTLAPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals